GlassScriptPhysician profile
Samuel R Carter
NPI 1760428973
$12,485.34
in general payments reported to CMS, 2019-2025
37 companies · $1,619 in 2025
The $1,619 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,189 · 2020: $1,854 · 2021: $1,852 · 2022: $2,148 · 2023: $1,876 · 2024: $1,947 · 2025: $1,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,417 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,417.43 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,544.24 | 2019-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $1,226.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $905.84 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbott Laboratories | $870.19 | 2019-2025 | Freestyle Libre |
| Lilly USA, LLC | $861.43 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $819.76 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $776.46 | 2019-2025 | Trintellix |
| Pfizer INC. | $659.23 | 2019-2025 | |
| Baxter Healthcare | $643.00 | 2022 | |
| Welch Allyn | $526.44 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $493.95 | 2019-2023 | Livalo, Seglentis |
| Merck Sharp & Dohme LLC | $462.79 | 2019-2025 | Capvaxive, Verquvo, Belsomra |
| Dexcom, INC. | $375.63 | 2021-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $335.28 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Idorsia Pharmaceuticals US INC | $220.91 | 2022-2024 | Quviviq |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $209.83 | 2019-2025 | Ubrelvy, Qulipta, Synthroid |
| Sanofi-Aventis U.S. LLC | $207.74 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $143.35 | 2019-2024 | Xarelto |
| Currax Pharmaceuticals LLC | $143.07 | 2019-2025 | Contrave, Nexletol, Onzetra Xsail |
| Exact Sciences Corporation | $143.04 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $131.93 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $112.53 | 2021 | |
| Novartis Pharmaceuticals Corporation | $94.72 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $81.43 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $81.18 | 2022 | |
| Astellas Pharma US INC | $68.88 | 2021 | |
| Amarin Pharma, INC. | $50.00 | 2019-2021 | |
| Allergan, INC. | $47.20 | 2020 | |
| Sumitomo Pharma America, INC. | $42.21 | 2024-2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $40.16 | 2022 | |
| Insulet Corporation | $31.67 | 2024 | Omnipod |
| Axsome Therapeutics, INC. | $31.26 | 2024-2025 | Auvelity |
| Medtronic, INC. | $29.77 | 2021-2023 | Minimed 780g |
| Seqirus USA INC | $26.66 | 2025 | Flucelvax, Fluad |
| Medtronic Minimed, INC. | $23.15 | 2020 | |
| Eisai INC. | $13.01 | 2021 | |
| Genentech USA, INC. | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.